Semaglutide vs Tirzepatide: Which Is Better?

Semaglutide and tirzepatide are the two most important weight loss medications in use today. They work through related but different mechanisms, produce different average results, and carry different cost profiles. The choice between them matters for outcomes and often for affordability. This post explains the actual differences, what the head-to-head evidence shows, and how to think about which might fit your situation.

The Mechanism Difference: Single vs Dual Agonist

This is the core biological difference between the two medications.

Semaglutide is a GLP-1 receptor agonist. It activates the GLP-1 receptor in the pancreas, gut, and brain. This reduces appetite, slows gastric emptying, and improves insulin response. One receptor, one mechanism.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Adding GIP activation creates additional metabolic effects that appear to enhance weight loss beyond what GLP-1 alone produces.

The practical result: tirzepatide produces somewhat greater average weight loss, with similar overall side effect profile. The trade-off is that tirzepatide has less long-term safety data because it has been in clinical use for a shorter time.

Head-to-Head Weight Loss Data

The definitive study directly comparing these medications for weight loss is SURMOUNT-1 (tirzepatide) versus STEP 1 (semaglutide), plus a more recent head-to-head trial. The SURMOUNT-1 trial data shows a clear dose-response pattern across the three tirzepatide doses studied.

A SURMOUNT-1 trial of tirzepatide published in the New England Journal of Medicine demonstrated weight loss at 72 weeks across three doses:

• Tirzepatide 5 mg: 15.0 percent body weight loss at 72 weeks
• Tirzepatide 10 mg: 19.5 percent body weight loss
• Tirzepatide 15 mg: 20.9 percent body weight loss
• Placebo: 3.1 percent

Compared to semaglutide 2.4 mg at 14.9 percent in STEP 1, the gap at maximum dose is roughly 5 to 6 percentage points in favor of tirzepatide.

At 12 months, tirzepatide patients had lost an average of 15.3 percent of body weight versus 8.3 percent for semaglutide patients. The advantage for tirzepatide appeared consistently across subgroups. The data is consistent: tirzepatide produces more weight loss on average, though individual response still varies significantly.

Side Effect Comparison

Both medications share similar side effect profiles because they both activate GLP-1 receptors. Nausea is the most common adverse effect, occurring in 20 to 50 percent of patients on either medication, with rates trending higher during titration and gradually decreasing as the body adapts. Vomiting tends to occur at slightly higher rates on tirzepatide at high doses, while diarrhea, constipation, and fatigue occur at roughly similar rates between the two. Injection site reactions are mild and comparable on both.

Two safety considerations apply equally to both medications: the same class warning for pancreatitis (rare but possible), and the same contraindication for patients with a personal or family history of medullary thyroid carcinoma due to C-cell tumor concerns observed in animal studies. Gallbladder events appear at slightly higher rates on tirzepatide in some analyses, likely related to the faster and greater weight loss tirzepatide produces.

Patient experience varies significantly. Some patients tolerate semaglutide better; others tolerate tirzepatide better. There is no reliable way to predict this in advance, which is part of why clinical follow-up and dose titration matter more than the choice of medication itself.

Cost Comparison

The cost picture differs significantly depending on whether you pay brand-name retail or access compounded formulations through a licensed pharmacy. The table below summarizes typical monthly cost ranges as of 2026:

Retail pricing has tirzepatide slightly cheaper than semaglutide brand. Compounded pricing has semaglutide slightly cheaper than tirzepatide. Insurance coverage varies significantly and can flip these numbers, with some plans covering one medication generously while excluding the other entirely.

Note that in late 2024 and 2025, tirzepatide supply became more available than semaglutide at compounding pharmacies following FDA actions regarding compounded semaglutide availability. Access and pricing continue to evolve, and current FDA shortage status should be checked before committing to a compounded approach.

Dose Structure

Both medications require weekly subcutaneous injection and follow similar titration patterns, with monthly dose increases until reaching the maintenance dose or maximum tolerated dose. The titration is intentional: starting at low doses and gradually increasing allows the body to adapt and significantly reduces the gastrointestinal side effects that occur with sudden full-dose initiation.

The semaglutide titration schedule moves through five steps:

• Month 1: 0.25 mg weekly
• Month 2: 0.5 mg
• Month 3: 1.0 mg
• Month 4: 1.7 mg
• Month 5+: 2.4 mg (maintenance)

The tirzepatide titration moves through similar monthly steps but with different absolute doses and a higher ceiling:

• Month 1: 2.5 mg weekly
• Month 2: 5 mg
• Month 3: 7.5 mg
• Month 4: 10 mg
• Month 5+: 12.5 mg, with optional increase to 15 mg

Tirzepatide offers more dose flexibility at the top end (12.5 or 15 mg), giving clinicians more room to titrate for specific patient needs. Semaglutide tops out at 2.4 mg for chronic weight management.

Who Might Do Better on Semaglutide

Despite tirzepatide producing greater average weight loss, several patient profiles often respond better to semaglutide. Patients who need the strongest long-term safety data benefit from semaglutide’s longer history in clinical use. Patients with established cardiovascular disease have a meaningful reason to consider semaglutide specifically: the SELECT trial gave semaglutide an FDA-approved cardiovascular benefit claim that tirzepatide does not yet have.

Budget-constrained patients accessing compounded products may find semaglutide slightly cheaper at the compounding pharmacy level, though the difference is often modest. Patients who have already responded well to semaglutide should generally continue rather than switch without clinical reason. A small subset of patients are sensitive to GIP-mediated side effects and tolerate semaglutide more comfortably than tirzepatide, though this is uncommon and difficult to predict before starting treatment.

Who Might Do Better on Tirzepatide

For most patients without specific reasons favoring semaglutide, tirzepatide is the default choice based on greater average weight loss. Patients with more weight to lose benefit from tirzepatide’s higher ceiling effect, particularly those with BMI above 35 where the additional 5 to 6 percentage points of weight loss translates to substantial real-world difference.

Patients who have plateaued on maximum semaglutide dose are common candidates for switching, with many seeing renewed weight loss after the transition. Patients with type 2 diabetes often respond particularly well to the dual mechanism, which typically produces better HbA1c control at equivalent weight loss levels than semaglutide alone. Patients who need additional appetite suppression beyond what semaglutide provides, or who have experienced minimal response to semaglutide after a full titration period, are also good candidates for the switch.

Switching Between Semaglutide and Tirzepatide

Moving between the two medications is straightforward clinically. The general protocol involves stopping one medication, waiting approximately one week to allow the previous medication to clear, then starting the new medication at its standard starting dose.

Semaglutide to tirzepatide: Stop semaglutide. Wait 1 week. Start tirzepatide at 2.5 mg and titrate normally. Some clinicians start at 5 mg for patients who had tolerated high doses of semaglutide, though this is off-label practice and not appropriate for every patient.

Tirzepatide to semaglutide: Stop tirzepatide. Wait 1 week. Start semaglutide at 0.25 mg and titrate. Expect possible lower response since tirzepatide is generally more potent at maximum dose.

Switching is sometimes done for cost reasons (insurance covers one but not the other), for plateau breakthrough when weight loss has stalled, or for side effect management when one medication is better tolerated than the other.

Cardiovascular and Metabolic Outcomes

Beyond weight loss, both medications produce improvements in cardiometabolic health. Semaglutide has more robust evidence for cardiovascular event reduction thanks to the SELECT trial, which showed a 20 percent reduction in major cardiovascular events in patients with overweight or obesity plus pre-existing cardiovascular disease.

Tirzepatide has shown strong improvements in blood pressure, triglycerides, and HbA1c, but the cardiovascular outcomes trial (SURPASS-CVOT) is still ongoing. Preliminary data suggests tirzepatide will show comparable cardiovascular benefit, but the evidence base is not yet complete.

For patients with established cardiovascular disease, semaglutide currently has the more established protective claim. For patients with type 2 diabetes and obesity, both show meaningful metabolic improvements, with tirzepatide typically producing greater reductions in HbA1c at equivalent weight loss levels.

Liver markers, inflammation markers, and sleep apnea severity also tend to improve on both medications, roughly proportional to weight loss achieved. These secondary benefits are often underappreciated but matter clinically, particularly for patients with metabolic syndrome or fatty liver disease.

Availability and Supply Considerations

Both medications have experienced supply constraints at various points since 2022. Brand-name manufacturers (Novo Nordisk for semaglutide, Eli Lilly for tirzepatide) have expanded production capacity significantly, and supply is generally stable as of 2026.

Compounded supply has fluctuated based on FDA regulatory status. When a medication is declared no longer in shortage, compounding pharmacies must typically stop producing copies. This has affected compounded semaglutide availability at various points. Current FDA shortage status should be checked before committing to a compounded approach, and a clinician can typically advise on what is currently available through their preferred compounding pharmacy network.

The Honest Choice

If cost and access were equal, tirzepatide would be the default choice for most patients due to greater average weight loss. The reality is that cost and insurance coverage often dictate the actual choice. Many patients start on whichever their insurance covers or whichever is available through their clinic at an affordable price.

Neither medication is universally better. Some patients who responded poorly to one respond well to the other. A few patients are best off on semaglutide despite tirzepatide being available, because they tolerate it better or their insurance covers it fully. Clinical judgment that accounts for individual factors beats generic recommendations.

What is clear: either of these medications, used correctly alongside appropriate lifestyle support, produces dramatically better results than nothing or older weight loss approaches. The right choice between them is secondary to the choice to start treatment at all.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Medical Director at Tactus Health. Dual board-certified nurse practitioner specializing in medical weight loss, hormone therapy, and metabolic health. Sugar Hill, GA with telehealth for Georgia patients.